Blockchain Registration Transaction Record

Clene Inc. Closes $7.3 Million Funding Round for Neurodegenerative Disease Treatment

Clene Inc. has successfully closed a $7.3 million funding round to support research into neurodegenerative diseases, including ALS, MS, and PD. The funding will also help advance their lead drug candidate, CNM-Au8, offering hope for patients with these conditions.

This news matters as it showcases Clene's efforts to secure funding for their research into neurodegenerative diseases, offering hope for patients with conditions like ALS. The success of their funding efforts and the progress of their lead drug candidate could potentially lead to new treatment options and improved quality of life for patients with these debilitating conditions.